SomnoMed (ASX:SOM) Long-Term Debt: A$4.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SOM SomnoMed Ltd ASX:SOM
49 GF Score
Price A$0.46
GF Value A$0.45
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Long-Term Debt?

SomnoMed ASX:SOM 49 Long-Term Debt is A$4.1 Mil as of Dec. 2025. GuruFocus rates ASX:SOM with a GF Score™ of 49/100 and a GF Value™ of A$0.45 (Fairly Valued). The stock has 3 warning signs investors should review.

SomnoMed's Long-Term Debt for the quarter that ended in Dec. 2025 was A$4.1 Mil.

SomnoMed's quarterly Long-Term Debt declined from Dec. 2024 (A$3.7 Mil) to Jun. 2025 (A$0.4 Mil) but then increased from Jun. 2025 (A$0.4 Mil) to Dec. 2025 (A$4.1 Mil).

SomnoMed's annual Long-Term Debt declined from Jun. 2023 (A$16.4 Mil) to Jun. 2024 (A$0.7 Mil) and declined from Jun. 2024 (A$0.7 Mil) to Jun. 2025 (A$0.4 Mil).

SomnoMed  (ASX:SOM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

SomnoMed Long-Term Debt Related Terms

SomnoMed Long-Term Debt Historical Data

* Premium members only.

The historical data trend for SomnoMed's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomnoMed Long-Term Debt Chart

SomnoMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.35 2.01 16.36 0.71 0.45

SomnoMed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.69 0.71 3.69 0.45 4.11
ASX:SOM
49GF Score
SomnoMed Ltd ASX:SOM
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$4.1 Mil mean?
SomnoMed (ASX:SOM) has a Long-Term Debt of A$4.1 Mil as of Dec. 2025.
Is SomnoMed's Long-Term Debt too high?
SomnoMed's current Long-Term Debt is A$4.1 Mil. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Long-Term Debt compare to ABT and SYK?
SomnoMed's Long-Term Debt of A$4.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. SomnoMed's current Long-Term Debt is A$4.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (ASX:SOM) is currently considered Fairly Valued. The stock's GF Value™ is A$0.45, compared to a current price of A$0.46 — trading 2.2% above its estimated fair value. The current Long-Term Debt is A$4.1 Mil. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For SomnoMed (ASX:SOM), the current Long-Term Debt is A$4.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (ASX:SOM) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of A$0.46 is trading 2.2% above its estimated GF Value™ of A$0.45. GuruFocus considers SomnoMed to be Fairly Valued.

Key valuation signals for ASX:SOM:

  • Long-Term Debt: A$4.1 Mil
  • GF Value™: A$0.45 vs. price of A$0.46 (2.2% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges SOMNF:USARJV:Germany
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for ASX:SOM

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price
A$0.45
GF Value